[1]华氏巨球蛋白血症1例 [2]BTK抑制剂BGB-3111治疗复发或难治型华氏巨球蛋白血症的临床研究 [3]硼替佐米联合地塞米松治疗华氏巨球蛋白血症的疗效观察 [4]淋巴浆细胞淋巴瘤/华氏巨球蛋白血症诊断与治疗中国专家共识（2016年版） [5]一项在华氏巨球蛋白血症患者中评估BGB-11417的有效性和安全性的研究 [6]The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains [7]T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape [8]Clinical and Pathological Implications of Increases in Tonsillar CD19+CD5+ B Cells, CD208+ Dendritic Cells, and IgA1-positive Cells of Immunoglobulin A Nephropathy [9]Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma [10]便携式一体化腹膜外腔扩张器